Clin Endocrinol:儿童创伤性脑损伤后是否需行垂体功能评估?

2014-01-22 佚名 不详

关于成人创伤性脑损伤(TBI)后垂体功能减退症的研报道究并不少见,然而,儿童创伤性脑损伤患者的相关资料却少之甚少。近期,一项针对儿童、青少年和青年人创伤性脑损伤患者的长期前瞻性研究结果发表于《临床内分泌学》杂志。 受试对象 符合纳入标准的患者共51人,对其中的37名患儿(年龄在2个月-19.9岁)进行了为期一年的跟踪随访。在创伤性脑损伤后的3个月和12个月分别评

关于成人创伤性脑损伤(TBI)后垂体功能减退症的研报道究并不少见,然而,儿童创伤性脑损伤患者的相关资料却少之甚少。近期,一项针对儿童、青少年和青年人创伤性脑损伤患者的长期前瞻性研究结果发表于《临床内分泌学》杂志。【原文下载】


受试对象

符合纳入标准的患者共51人,对其中的37名患儿(年龄在2个月-19.9岁)进行了为期一年的跟踪随访。在创伤性脑损伤后的3个月和12个月分别评估上述患儿的临床特点并检测基线内分泌功能指标,6岁及以上患儿接受两项兴奋试验(胰岛血糖素兴奋试验和生长激素兴奋试验)检查。

结果

在6岁及以上患儿(n=23)中,有11人(47.8%)在创伤性脑损伤后3个月的生长激素峰值低于正常,其中有8人(34%)生长激素异常持续至创伤性脑损伤后一年。生长激素反应与颅脑损伤的严重程度(根据GCS评分和Marshall分级标准)无相关性。所有患儿的生长速率除1人外均在正常范围。生长激素反应低下者的体质指数(BMI)标准差比值(SDS)均显著升高。23名患儿中有10人的皮质醇分泌节律紊乱,1年后除3人外均恢复正常分泌节律。所有患儿中仅有1人接受促性腺激素释放激素(GnRH)兴奋试验时存在垂体反应性。6岁以下患儿均未出现相关临床症状及激素水平的异常。

结论

在对创伤性脑损伤患儿进行前瞻性随访后得出如下结论:首先,目前没有能够准确预测创伤性脑损伤后垂体功能障碍的有效指标,其次,我们要避免垂体功能障碍相关的潜在并发症。对于青春期后的儿童或尚处于生长发育正常的青春期前儿童,在创伤性脑损伤后和/或生长激素治疗之前是否需要进行系统性内分泌功能筛查还需要更多的前瞻性临床试验数据。

原文出处:

Casano-Sancho P, Suárez L, Ibáñez L, García-Fructuoso G, Medina J, Febrer A.Pituitary dysfunction after traumatic brain injury in children: is there a need for ongoing endocrine assessment?Clin Endocrinol (Oxf). 2013 May 7. doi: 10.1111/cen.12237. 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025417, encodeId=a5eb202541ea2, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon Mar 31 19:32:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335052, encodeId=e7fe1335052bb, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396807, encodeId=9403139680ef1, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458235, encodeId=77ec145823542, content=<a href='/topic/show?id=beff41500cf' target=_blank style='color:#2F92EE;'>#垂体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41500, encryptionId=beff41500cf, topicName=垂体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f1a6007916, createdName=chendoc244, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=)]
    2014-03-31 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025417, encodeId=a5eb202541ea2, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon Mar 31 19:32:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335052, encodeId=e7fe1335052bb, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396807, encodeId=9403139680ef1, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458235, encodeId=77ec145823542, content=<a href='/topic/show?id=beff41500cf' target=_blank style='color:#2F92EE;'>#垂体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41500, encryptionId=beff41500cf, topicName=垂体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f1a6007916, createdName=chendoc244, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025417, encodeId=a5eb202541ea2, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon Mar 31 19:32:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335052, encodeId=e7fe1335052bb, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396807, encodeId=9403139680ef1, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458235, encodeId=77ec145823542, content=<a href='/topic/show?id=beff41500cf' target=_blank style='color:#2F92EE;'>#垂体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41500, encryptionId=beff41500cf, topicName=垂体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f1a6007916, createdName=chendoc244, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2025417, encodeId=a5eb202541ea2, content=<a href='/topic/show?id=66f93204223' target=_blank style='color:#2F92EE;'>#创伤性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32042, encryptionId=66f93204223, topicName=创伤性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=325a197, createdName=amyloid, createdTime=Mon Mar 31 19:32:00 CST 2014, time=2014-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1335052, encodeId=e7fe1335052bb, content=<a href='/topic/show?id=e7cc32022c7' target=_blank style='color:#2F92EE;'>#创伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32022, encryptionId=e7cc32022c7, topicName=创伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396807, encodeId=9403139680ef1, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458235, encodeId=77ec145823542, content=<a href='/topic/show?id=beff41500cf' target=_blank style='color:#2F92EE;'>#垂体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41500, encryptionId=beff41500cf, topicName=垂体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f1a6007916, createdName=chendoc244, createdTime=Fri Jan 24 00:32:00 CST 2014, time=2014-01-24, status=1, ipAttribution=)]
    2014-01-24 chendoc244

相关资讯

NEJM:金刚烷胺可加快脑损伤后意识恢复

     《新英格兰医学杂志》NEJM 3月1日发表的一项国际、随机、双盲、安慰剂对照研究显示,为期4周的金刚烷胺治疗能够加快创伤性脑损伤(TBI)后意识障碍患者的功能恢复速度[N. Engl. J. Med. 2012;366:819-26]。          在这项研究中,新泽西州JFK约翰逊康复研究所的Jo

Marshall评分可更好地预测创伤性脑损伤早期死亡

  芝加哥——北美放射学会(RSNA)2012年会上公布的一项获奖研究显示,与鹿特丹CT评分系统相比,Marshal CT评分系统能够更好地预测创伤性脑损伤(TBI)患者的早期死亡。   Marshall评分和鹿特丹评分是两种最常用的放射学评分系统,但两者对CT表现的分类不同。Marshall评分系统包括基底池状态、中线移位>5 mm及出血肿块,而鹿特丹评分系统包括基底池、中线移位>5 m

LANCET NEUROL:创伤性脑损伤发病率高于官方公布的6倍

      一项最新的以人群为基础的研究表明,创伤性脑损伤(TBI)的真实发生率大约 比官方数字高6倍。这一研究结果发表于最新一期的《柳叶刀神经病学》杂志。        新西兰奥克兰理工大学首席研究员Valery Feigin教授在一份新闻稿中说:“我们研究是首次涵盖较多轻度TBI患者的研究,而此类研究通常不住

静推高渗液体对不显著改善严重TBI患者预后

  一项多国研究显示,对非低血容量性休克的严重创伤性脑损伤(TBI)患者,予高渗性液体不显著改善6个月时神经系统预后或生存率。研究发表于《美国医学会杂志》(JAMA) 2010, 304(13):1455。   研究选取1087例未达低血容量性休克标准的钝性外伤患者(年龄≥15岁,院前GCS≤8),分别给250 mL 7.5%盐水/6%右旋糖酐70,7.5%盐水或0.9%盐水静推, 观察病情改善率

慢性主观性头晕的临床诊治

长期以来,没有明确前庭功能障碍的慢性头晕被称作精神性头晕,这一模糊的定义未能显示出慢性头晕患者的精神因素和神经科-耳科因素之间的复杂关系。20世纪70~90年代,美国和欧洲的研究者报道了一系列慢性头晕患者的临床症状,如Brandt等描述的“恐惧性位置性眩晕(phobic positional vertigo) ”,Bronstein等描述的视觉性眩晕(visual vertigo)。这些术语均